Altimmune Future Growth

Future criteria checks 2/6

Altimmune is forecast to grow earnings and revenue by 18.6% and 83.2% per annum respectively. EPS is expected to grow by 28.3% per annum. Return on equity is forecast to be -48.2% in 3 years.

Key information

18.6%

Earnings growth rate

28.3%

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth rate83.2%
Future return on equity-48.2%
Analyst coverage

Good

Last updated05 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:3G0 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-176-96-918
12/31/202525-102-78-88
12/31/20240-96-78-838
9/30/20240-104-78-78N/A
6/30/20240-101-71-71N/A
3/31/20240-93-73-73N/A
12/31/20230-88-76-76N/A
9/30/20230-78-77-77N/A
6/30/20230-81-71-71N/A
3/31/20230-85-69-68N/A
12/31/20220-85-63-63N/A
9/30/20223-87-67-67N/A
6/30/20223-97-70-70N/A
3/31/20224-102-80-72N/A
12/31/20214-97-91-78N/A
9/30/20213-84-82-70N/A
6/30/20216-68-74-61N/A
3/31/20217-60-54-50N/A
12/31/20208-49-35-34N/A
9/30/20206-43-23-23N/A
6/30/20204-36-16-16N/A
3/31/20205-22-12-12N/A
12/31/20196-21-10-10N/A
9/30/20198-42-13-13N/A
6/30/201910-34-12-11N/A
3/31/201911-40-8-8N/A
12/31/201810-42-10-9N/A
9/30/201811-29-10-9N/A
6/30/201813-58N/A-12N/A
3/31/201813-52N/A-20N/A
12/31/201711-51N/A-20N/A
9/30/20179-43N/A-17N/A
6/30/20175-16N/A-15N/A
3/31/20173-14N/A-8N/A
12/31/20163-11N/A-6N/A
9/30/20163-10N/A-7N/A
12/31/20155-7N/A-5N/A
12/31/20146-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3G0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 3G0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 3G0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 3G0's revenue (83.2% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 3G0's revenue (83.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3G0 is forecast to be unprofitable in 3 years.


Discover growth companies